Need professional-grade analysis? Visit stockanalysis.com
$347.37M
N/A
N/A
N/A
Ovid Therapeutics Inc (OVID) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $2.91, up 3.93% from the previous close.
Over the past year, OVID has traded between a low of $0.27 and a high of $2.96. The stock has gained 903.4% over this period. It is currently 969.1% above its 52-week low.
Ovid Therapeutics Inc has a market capitalization of $347.37M.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Side-by-side comparison against top Healthcare peers.